Aim: To evaluate correlation between esophageal and hematological toxicity and chemotherapy (CT) in patients treated with concurrent RCT for LA NSCLC. We evaluate also dosimetric parameters of irradiated esophageal volume. Methods: 37 patients, 26 female and 11 male, with mean age of 62.3 years (range 43-75) were evaluated. CT schedules were Cisplatin-Vinorelbine (CDDP 75 mg/m2 d1-VNR 25 mg/m2 d1-8 q21) in 15 cases, Cisplatin-Docetaxel (CDDP 75 mg/m2 d1-TXT 75 mg/m2 d1 q21) in 22 cases. Histology was adenocarcinoma in 16 cases, squamous cells carcinoma in 21 cases. All patients received radiotherapy (RT) with radical dose (mean dose: 64 Gy, range 60-70 Gy). We evaluate acute esophageal and hematological toxicity according to Radiotherapy Oncology Group (RTOG) scales during treatment and for 3 months after the treatment end. We evaluate the impact of different treatment CT schedule in the development of esophageal toxicity. We also reviewed dosimetric parameters relative to irradiated esophageal volume and occurrence of toxicity. Results: Twelve patients experienced grade 1-3 leukopenia; 2 patients experienced grade 2 or 3 and 10 patients experienced grade 1 to 2 anemia. Twenty-two patients experienced esophageal toxicity, with a maximum grade of 1. Only 2 patients needed interruption of RT because of esophagitis. No correlation was found between hematological toxicity or schedule of CT and esophageal toxicity. We found a correlation between irradiated esophageal volume and the occurrence of esophageal toxicity, according to literature results. In particular we found a statistically significant correlation between the increase of V20 (p: 0.036); V40 (p: 0.027) and V45 value (p: 0.024) and the occurrence of esophageal toxicity. Conclusions: There is no significant correlation between CT, hematological and esophageal toxicity in patients treated with concurrent RCT for LA NSCLC. This confirm the safety and feasibility of these CT schedules in concomitant setting in LA NSCLC and the importance of respecting constraints for esophageal toxicity prevention.
91P * DEFINITIVE CONCOMITANT RADIOCHEMOTHERAPY (RCT) TREATMENT FOR LOCALLY ADVANCED (LA) NON SMALL CELL LUNG CANCER (NSCLC): EVALUATION OF HEMATOLOGICAL AND ESOPHAGEAL TOXICITY IN THE RADIATION ONCOLOGY DEPARTMENT OF UNIVERSITY OF FLORENCE EXPERIENCE / Scotti, V.; Scartoni, D.; Furfaro, I. F.; Simontacchi, G.; De Luca Cardillo, C.; Agresti, B.; Talamonti, C.; Livi, L.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - ELETTRONICO. - 26:(2015), pp. i27-i27. [10.1093/annonc/mdv049.11]
91P * DEFINITIVE CONCOMITANT RADIOCHEMOTHERAPY (RCT) TREATMENT FOR LOCALLY ADVANCED (LA) NON SMALL CELL LUNG CANCER (NSCLC): EVALUATION OF HEMATOLOGICAL AND ESOPHAGEAL TOXICITY IN THE RADIATION ONCOLOGY DEPARTMENT OF UNIVERSITY OF FLORENCE EXPERIENCE
SCOTTI, VIERI;SCARTONI, DANIELE;SIMONTACCHI, GABRIELE;DE LUCA CARDILLO, CARLA;AGRESTI, BENEDETTA;TALAMONTI, CINZIA;LIVI, LORENZO
2015
Abstract
Aim: To evaluate correlation between esophageal and hematological toxicity and chemotherapy (CT) in patients treated with concurrent RCT for LA NSCLC. We evaluate also dosimetric parameters of irradiated esophageal volume. Methods: 37 patients, 26 female and 11 male, with mean age of 62.3 years (range 43-75) were evaluated. CT schedules were Cisplatin-Vinorelbine (CDDP 75 mg/m2 d1-VNR 25 mg/m2 d1-8 q21) in 15 cases, Cisplatin-Docetaxel (CDDP 75 mg/m2 d1-TXT 75 mg/m2 d1 q21) in 22 cases. Histology was adenocarcinoma in 16 cases, squamous cells carcinoma in 21 cases. All patients received radiotherapy (RT) with radical dose (mean dose: 64 Gy, range 60-70 Gy). We evaluate acute esophageal and hematological toxicity according to Radiotherapy Oncology Group (RTOG) scales during treatment and for 3 months after the treatment end. We evaluate the impact of different treatment CT schedule in the development of esophageal toxicity. We also reviewed dosimetric parameters relative to irradiated esophageal volume and occurrence of toxicity. Results: Twelve patients experienced grade 1-3 leukopenia; 2 patients experienced grade 2 or 3 and 10 patients experienced grade 1 to 2 anemia. Twenty-two patients experienced esophageal toxicity, with a maximum grade of 1. Only 2 patients needed interruption of RT because of esophagitis. No correlation was found between hematological toxicity or schedule of CT and esophageal toxicity. We found a correlation between irradiated esophageal volume and the occurrence of esophageal toxicity, according to literature results. In particular we found a statistically significant correlation between the increase of V20 (p: 0.036); V40 (p: 0.027) and V45 value (p: 0.024) and the occurrence of esophageal toxicity. Conclusions: There is no significant correlation between CT, hematological and esophageal toxicity in patients treated with concurrent RCT for LA NSCLC. This confirm the safety and feasibility of these CT schedules in concomitant setting in LA NSCLC and the importance of respecting constraints for esophageal toxicity prevention.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
